Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
In this article, four different mathematical models of chemotherapy from the literature are investigated with respect to optimal control of drug treatment schedules. The various models are based on two different sets of ordinary differential equations and contain either chemotherapy, immunotherapy, anti-angiogenic therapy or combinations of these. Optimal control problem formulations based on these models are proposed, discussed and compared. For different parameter sets, scenarios, and objective functions optimal control problems are solved numerically with Bock's direct multiple shooting method. In particular, we show that an optimally controlled therapy can be the reason for the difference between a growing and a totally vanishing tumor in comparison to standard treatment schemes and untreated or wrongly treated tumors. Furthermore, we compare different objective functions. Eventually, we propose an optimization-driven indicator for the potential gain of optimal controls. Based on this indicator, we show that there is a high potential for optimization of chemotherapy schedules, although the currently available models are not yet appropriate for transferring the optimal therapies into medical practice due to patient-, cancer-, and therapy-specific components.
Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Im Neuenheimer Feld 368, 69120 Heidelberg, Germany. michael.engelhart@iwr.uni-heidelberg.de
Michael
M
Engelhart
Dirk
D
Lebiedz
Sebastian
S
Sager
D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003198:Computer Simulation; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents